Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 801 results for "continuous renal replacement therapy"

FDA approves Baxter's Phoxillum Renal Replacement Solution
Pharmaceutical Business Review

2/2/15 - Baxter Receives FDA Approval for PHOXILLUM Solution f...

By a News Reporter-Staff News Editor at Pharma Business Week Baxter International Inc. (NYSE:BAX) announced the United States Food and Drug Administration (FDA) has approved PHOXILLUM Renal Replacement Solutions (BK4/2.5 and B22K4/0) as replacement ... Pharmacy Choice, 3 weeks ago

3 images for "continuous renal replacement therapy"

Chicago Sun-Times, 1 month ago
MDLinx, 1 month ago
MDLinx, 1 month ago

Some metabolic issues should not be neglected when using citrate for continuous renal replacement therapy!

We read with great interest the paper by Schilder and colleagues on citrate anticoagulation versus systemic heparinisation (CASH) [ 1 ] and its related commentary [ 2 ], but would like to comment on two important metabolic issues. First, ...
 Critical Care2 weeks ago

Correction of Hyper- and Hyponatraemia during Continuous Renal Replacement Therapy

General Please address all your queries or problem reports to the Pay-per-View Customer Service at referring to PPV or PPV account. 1. All payments are by credit card only. The transaction is secure: standard-procedure SSL or ...
 Sexual Development1 month ago
Seeking Alpha

Medgenics' TARGT Therapy Continues To Show Promising Clinical Results

Feb. 16, 2015 12:15 PM ET | About: Medgenics (MDGN) by: Subscribers to SA PRO had an early look at this article. Learn more about PRO » Summary MDGN-201 EPO Clinical Trial Continues to Show Promising Results. One Patient Has Now Been ...
 Seeking Alpha1 week ago Medgenics Reports Fourth Quarter and Full Year 2014 Financial Results  Benzinga.com2 weeks ago Ipsen: Sales in the Fourth Quarter and Full Year 2014  MoneyShow.com3 weeks ago

Rockwell Medical Reports Fourth Quarter 2014 Results

Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary ...
 Individual.com3 days ago Rockwell Medical Schedules Fourth Quarter Earnings Call  Individual.com6 days ago FDA approves Natpara for injection to control hypocalcemia in patients with hypoparathyroidism  Pharmaceutical Business Review1 month ago FDA Approves Rockwell Medicall's Triferic For Iron Replacement And Maintenance Of Hemoglobin In Hemodialysis Patient  BioSpace1 month ago

Optimizing Therapy for VRE Bacteremia in Children

Hidron AI, Edwards JR, Patel J, et al . NHSN annual update: antimicrobialresistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease ...
 General Medicine eJournal1 week ago

Home Dialysis Uptick Slow, But Gaining Momentum

NEW ORLEANS — Home dialysis continues to gain recognition as a safe and practical alternative to in-center dialysis for patients who need renal replacement therapy. However, appropriate training and competency in its delivery is lacking, according ...
 Dermatology Online Journal3 weeks ago

R KLaxmantaken off ventilator support

Comment · print · T T T+· T- TOPICS While legendary cartoonist R.K. Laxman continues to be in a critical condition, he has been taken off ventilator support, which brings hope of a recovery, said medical sources on Friday. Citing a ...
 The Hindu1 month ago Veteran cartoonist RK Laxman's health improves  DNA India1 month ago R.K.Laxmantaken off ventilator support  The Hindu1 month ago

Diaverum Enters Asian Market by Acquiring Kidney Centres in Kazakhstan

[January 16, 2015] Diaverum, one of the world's leading renal care providers, today announced the acquisition of Nefros Asia in Kazakhstan with nine kidney centres across the country. The centres will shortly begin the ...
 TMC Net1 month ago

Celldex Therapeutics, Inc. And Bristol-Myers Squibb Company Announce Initiation Of Phase 1/2 Combination Study Of Varlilumab And Opdivo® In Advanced Refractory Solid Tumors

HAMPTON, N.J., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) and Bristol Myers-Squibb (NYSE:BMY) today announced the initiation of a Phase 1/2 dose escalation and cohort expansion study examining the investigational ...
 BioSpace1 month ago Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo(R) in Advanced Refractory Solid Tumors  Wall Street Business Network1 month ago Bristol Myers Squibb : Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo® in Advanced Refractory Solid Tumors  4 Traders1 month ago SHIRE PLC - 10-K - : Management's discussion and analysis of financial condition and results of operations  Pharmacy Choice4 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less